Abstract
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to prevent or minimize this toxicity in future clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams R. D. and Victor M.Principles of Neurology 4th ed. McGraw-Hill, 1989.
Bookman M. A., Godfrey S., Padavic K., Griffin J. P., Corda T., Hamilton R. F., Ozoles E. S., and Groves E. S. (1990) Second International Symposium on Immunotoxins, Lake Buena Vista, FL.
Borges L. F., Elliott P. J., Gill R., Iversen S. D., and Iversen L. L. (1985) Selective extraction of small and large molecules from the cerebrospinal fluid by Purkinje neurons.Science 228, 346–348.
Fitzgerald D. and Pastan I. (1989) Targeted toxin therapy for the treatment of cancer.J. Nat. Cancer Inst. 89, 1455–1463.
Gould B. J., Borowitz E. S., Groves P. W., Carter D. A., Weiner L. M., and Frankel A. E. (1989) Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies.J. Nat. Cancer Inst. 89, 775–781.
Hertler A. A., Spitler L. E., and Frankel A. E. (1987) Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.Cancer Drug Del. 4, 245–253.
Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., and Frankel A. (1988) A phase I study of T101-ricin A chian immunotoxin in refractory chronic lymphocytic leukemia.J. Biol. Resp. Modif. 7, 97–113.
Johnson V. G., Wrobel C., Wilson D., Zovickian J., Greenfield L., Oldfield, E. H., and Youle R. J. (1989) Improved tumor specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia.J. Neurosurg. 70, 240–248.
Lashford L. S., Davies G., Richardson R. B., Bourne S. P., Bullimore J. A., Eckert H., Kemshead J. T., and Coakham H. B. (1988) A pilot study of I-131 monoclonal antibodies in the treatment of leptomenningeal tumors.Cancer 61, 857–868.
Laske D. W., Muraszko K. M., Oldfield E. H., DeVroom H. L., Sung C., Dedrick R. L., Simon T. R., Colandrea J., Copeland C., Katz, D., Groves E. S., Greenfield L., Houston L. L., and Youle R. J. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. 1993, submitted.
Mendelson J. (1991) Immunotoxins: Prospects and problems (editorial).J. Clin. Oncol. 9, 2088–2090.
Muraszko K., Sung C., Walbridge S., Greenfield L., Dedrick R., Oldfield E. H., and Youle R. J. (1993) Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.Cancer Res. 53, 3752–3757.
Pai L. H., Bookman M. A., Ozols R. F., Young R. C., Smith II, J. W., Longo D. L., Gould B., Frankel A., McClay E. F., Howell S., Reed E., Willingham M. C., Fitzgerald D. J., and Pastan I. (1991) Clinical evaluation of intraperitoneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.J. Clin. Oncol. 9, 2095–2103.
Pappenheimer A. M., Harper A. A., Moynihan M., and Brockes J. P. (1981) Diptheria toxin and related proteins: effect of route of administration on toxicity and the determination of cytotoxicity for various cultured cells.J. Infect. Dis. 145, 94–102.
Riedel C. J., Muraszko K. M., and Youle R. J. (1990) Diphtheria toxin mutant selectivity kills cerebellar Purkinje neurons.Proc. Natl. Acad. Sci. USA 87, 5051–5055.
Spitler L. E., del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller W., Harkonen S., Rosendorf L. L., Lee H. M., Mischak R. P., Kawahata R. T., Stoudemeir J. B., Fradkin L. B., Bautista E. E., and Scannon P. J. (1991) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.Cancer Res. 47, 1717–1723.
Stone M., Amlot P., Fay J., Till M., Ghetie V., Collins R., May R. Newman J., Clark P., Thorpe P., Uhr J., and Vitetta E. S. (1990) Immunotoxin therapy of B cell lymphoma.Blood 76, 374a.
Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Gheti V., Uhr J. W., and Thorpe P. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma.Cancer Res. 51, 4052–4058.
Weiner L. M., O’Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J., Konrad M. S., and Groves E. S. (1989) Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies.Cancer Res. 49, 4062–4067.
Youle R. J. (1991) Mutations in diphtheria toxin to improve immunotoxin selectivity and understand toxin entry into cells.Sem. Cell Biol. 2, 39–45.
Zovickian J., Johnson V. G., and Youle R. J. (1987) Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibodyricin immunotoxin.J. Neurosurg. 66, 850–861.
Zovickian J. and Youle R. (1988) Efficacy of intrathecal immunotoxin in an animal model of leptomeningeal neoplasia.J. Neursurg. 68, 767–774.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ilercil, O., Laske, D.W., Walbridge, S. et al. Neurotoxicity of immunotoxins. Molecular and Chemical Neuropathology 21, 379–386 (1994). https://doi.org/10.1007/BF02815363
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02815363